FindTrial
Sign In

Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B

Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0000087
Enrollment
101
Registered
2011-01-25
Start date
2010-10-05
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ajou University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: naive patients with chronic hepatitis B who received 0.5mg entecavir once daily more than 12 months from Ajou University Hospital.

Exclusion criteria

Exclusion criteria: Patients who had hepatocellular carcinoma on presentation or other concomitant disease including hepatitis C, autoimmune hepatitis, alcoholic liver disease were excluded

Design outcomes

Primary

MeasureTime frame
negative HBV DNA PCR ;HBeAg loss or seroconversion—

Secondary

MeasureTime frame
HBsAg level—

Countries

Korea, Republic of

Contacts

Public ContactMyoung Hee Lee

Ajou University

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026